# TriPRIL (NCT05020444)

> TriPRIL CAR T Cells in Multiple Myeloma

No report yet. It can be ordered.

- Indication: relapsed or refractory multiple myeloma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05020444
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Marcela V. Maus, M.D.,Ph.D.
- Conditions: Multiple Myeloma; Multiple Myeloma in Relapse; Refractory Multiple Myeloma
- Interventions: TriPRIL CAR T Cells; Cyclophosphamide; Fludarabine
- Enrollment: 16
- Primary outcome: Incidence of adverse events (AEs)
- Primary outcome: Incidence of Dose Limiting Toxicity (DLT)

## Indexed commentary on TriPRIL so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 posts on X
- 1 YouTube video

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=tripril-nct05020444
